Edgewise Therapeutics
Highly Engaged Employees
Business Services · Colorado, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1715 38th St, Boulder, Colorado, 80301, ...Phone Number
(720) 262-7002Website
www.edgewisetx.comRevenue
$24.7 MillionStock Symbol
EWTXIndustry
About Edgewise Therapeutics
Edgewise Therapeutics Org Chart
Is Edgewise Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Edgewise Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Edgewise Therapeutics recently announced quarterly report
Product Launch: Get notified when Edgewise Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Edgewise Therapeutics
Click to see if Edgewise Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Edgewise Therapeutics has new funding data
Check out if Edgewise Therapeutics is spiking on competitors!
Edgewise Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Edgewise Therapeutics
Compare insights from companies similar to Edgewise Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Edgewise Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Edgewise Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Edgewise Therapeutics.
Edgewise Therapeutics financials insights
Gather financial insights about Edgewise Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$15.5M
Series B
$50M
Series C
$95M
Stock Offering
$202.4M
Edgewise Therapeutics Tech Stack
A closer look at the technologies used by Edgewise Therapeutics
Most Recent Scoops
Edgewise Therapeutics News & Media
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. SURESNES, France, July 13, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on June...Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG-7500...Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29,...
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Edgewise Therapeutics
EDGEWISE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. EDGEWISE has combined its expertise in muscle biology and small molecule engineering to build a proprietary, muscle focused drug discovery platform. The platform... Read More